Matt Abernethy insider trades
Matt Abernethy has filed 22 Form 4s with the SEC that we hold, for Neurocrine Biosciences INC (NBIX) (Chief Financial Officer) and Fate Therapeutics INC (FATE) (Director). Across all of them we count 0 purchases worth $0 and 24 sales worth $11.8M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($363.3K). The largest single trade was a sale of 14,100 shares of Neurocrine Biosciences INC worth $2.1M, dated 2024-08-13. Of 1 sale filed since we began reading the 10b5-1 checkbox, 1 (100%) was marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-12-03 and the latest 2026-09-15.
Neurocrine Biosciences INC (NBIX)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2021-12-01 | S, sale reported on Form 4 | 1,645 | $135.9K | 2021-12-03 | SEC |
| 2022-02-07 | S, sale reported on Form 4 | 2,030 | $164.0K | 2022-02-09 | SEC |
| 2022-02-07 | S, sale reported on Form 4 | 1,280 | $103.4K | 2022-02-09 | SEC |
| 2022-02-08 | S, sale reported on Form 4 | 980 | $78.1K | 2022-02-09 | SEC |
| 2023-01-31 | S, sale reported on Form 4 | 1,283 | $141.1K | 2023-02-02 | SEC |
| 2023-02-06 | S, sale reported on Form 4 | 1,280 | $135.3K | 2023-02-08 | SEC |
| 2023-02-07 | S, sale reported on Form 4 | 2,030 | $207.7K | 2023-02-08 | SEC |
| 2023-02-07 | S, sale reported on Form 4 | 11,491 | $1.2M | 2023-02-08 | SEC |
| 2023-02-07 | S, sale reported on Form 4 | 12,807 | $1.3M | 2023-02-08 | SEC |
| 2023-02-08 | S, sale reported on Form 4 | 980 | $102.1K | 2023-02-08 | SEC |
| 2023-08-21 | S, sale reported on Form 4 | 2,132 | $229.0K | 2023-08-23 | SEC |
| 2024-01-31 | S, sale reported on Form 4 | 1,283 | $180.5K | 2024-02-02 | SEC |
| 2024-02-06 | S, sale reported on Form 4 | 1,280 | $182.0K | 2024-02-08 | SEC |
| 2024-02-08 | S, sale reported on Form 4 | 980 | $131.5K | 2024-02-08 | SEC |
| 2024-02-13 | S, sale reported on Form 4 | 1,352 | $179.6K | 2024-02-15 | SEC |
| 2024-05-14 | S, sale reported on Form 4 | 15,000 | $2.0M | 2024-05-16 | SEC |
| 2024-05-15 | S, sale reported on Form 4 | 15,000 | $2.1M | 2024-05-16 | SEC |
| 2024-07-16 | S, sale reported on Form 4 | 900 | $135.0K | 2024-07-18 | SEC |
| 2024-08-13 | S, sale reported on Form 4 | 14,100 | $2.1M | 2024-08-15 | SEC |
| 2025-01-31 | S, sale reported on Form 4 | 1,283 | $196.1K | 2025-02-04 | SEC |
| 2025-02-10 | S, sale reported on Form 4 | 980 | $115.9K | 2025-02-12 | SEC |
| 2025-02-13 | S, sale reported on Form 4 | 1,352 | $158.0K | 2025-02-14 | SEC |
| 2025-02-13 | S, sale reported on Form 4 | 1,206 | $140.9K | 2025-02-14 | SEC |
| 2026-09-14 | S, sale reported on Form 4 | 2,311 | $363.3K | 2026-09-15 | SEC |
Fate Therapeutics INC (FATE)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1724097) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
